Press Releases

Nov 17, 2020
BeiGene Announces that RATIONALE 303 Trial of Tislelizumab in Non-Small Cell Lung Cancer Met the Primary Endpoint of Overall Survival at Interim Analysis    read more...
Nov 05, 2020
BeiGene Reports Third Quarter 2020 Financial Results    read more...
Nov 05, 2020
BeiGene Announces Data on BRUKINSA® (Zanubrutinib) and Tislelizumab to Be Presented at the 62nd ASH Annual Meeting    read more...
Oct 06, 2020
BioAtla and BeiGene Revise Global Development and Commercialization Agreement for Novel Conditionally Active Biologic CTLA-4 Candidate BA3071    read more...
Aug 06, 2020
BeiGene Reports Second Quarter 2020 Financial Results    read more...
Aug 05, 2020
BeiGene Announces Data on Tislelizumab and Pamiparib to Be Presented at the 2020 European Society for Medical Oncology (ESMO) Virtual Congress    read more...
Jul 27, 2020
Priority Review Granted to BeiGene’s New Drug Application of Pamiparib in Ovarian Cancer in China    read more...
Jul 17, 2020
BeiGene Announces Acceptance of a New Drug Application of Pamiparib in Ovarian Cancer in China    read more...
Jul 15, 2020
BeiGene Announces Closing of Approximately $2.08 Billion Registered Direct Offering    read more...
Jul 12, 2020
BeiGene Announces Pricing of Approximately $2.08 Billion Registered Direct Offering    read more...
Jul 02, 2020
BeiGene to Host Investor Conference Call and Webcast to Discuss the Company’s Early Development Pipeline and Research    read more...
Jul 01, 2020
BeiGene Announces Acceptance of a Supplemental New Drug Application for Tislelizumab in Patients with Previously Treated Unresectable Hepatocellular Carcinoma in China    read more...
Jul 01, 2020
BeiGene Announces Appointment of Angus Grant as Chief Business Executive    read more...
Jun 30, 2020
BeiGene Begins Commercializing XGEVA® (Denosumab) in China    read more...
Jun 19, 2020
BeiGene Announces Acceptance of a Supplemental New Drug Application for Tislelizumab in Combination with Chemotherapy in First-Line Advanced Non-Squamous Non-Small Cell Lung Cancer in China    read more...
Jun 18, 2020
BeiGene Announces European Medicines Agency Acceptance of its Marketing Authorization Application for BRUKINSA® (Zanubrutinib) for the Treatment of Patients with Waldenström’s Macroglobulinemia    read more...
Jun 12, 2020
BeiGene Presents Clinical Data on Zanubrutinib and Tislelizumab at the 25th European Hematology Association (EHA) Virtual Congress    read more...
Jun 05, 2020
BeiGene to Present at the Goldman Sachs 41st Annual Global Healthcare Conference    read more...
Jun 03, 2020
BeiGene Announces the Approval of BRUKINSA™ (Zanubrutinib) in China for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma and Relapsed/Refractory Mantle Cell Lymphoma    read more...
May 29, 2020
BeiGene Presents Phase 3 Data on Tislelizumab Combined with Chemotherapy for the Treatment of Patients with Advanced Squamous Non-Small Cell Lung Cancer at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program    read more...